Vomiting on Wegovy (Semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect

At a glance

• Incidence in trials: 24.8% on semaglutide 2.4 mg vs. 6.8% on placebo (STEP 1, NEJM 2021)
• Typical onset: Within 48 to 72 hours of each dose escalation step
• Peak window: Weeks 5 through 12, corresponding to the 1.0 mg and 1.7 mg dose tiers
• Resolution for most patients: By weeks 16 to 20 on stable 2.4 mg maintenance
• Severity breakdown: 81% of vomiting events classified as mild or moderate in STEP 1
• First-line management: Smaller meals, bland diet, oral ondansetron 4 to 8 mg as needed
• When to escalate: Vomiting more than 3 times daily, inability to keep down fluids for >12 hours, or signs of dehydration
• Discontinuation rate due to GI events: 4.5% across STEP 1 (FDA prescribing information)

Why Wegovy Causes Vomiting

Semaglutide triggers vomiting through two parallel pathways. In the gut, GLP-1 receptor activation slows gastric emptying by 25 to 40%, leaving food sitting in the stomach longer than the body expects (Halawi et al., Clin Gastroenterol Hepatol 2017). That gastric distension sends afferent vagal signals to the brainstem's area postrema, a region packed with GLP-1 receptors that sits outside the blood-brain barrier (Hayes et al., Endocrinology 2010). The combined peripheral fullness signal and direct central receptor stimulation lowers the threshold for the vomiting reflex, particularly when semaglutide concentrations are rising after a dose increase.

Because Wegovy uses a slow 16-week escalation schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg), each step up produces a transient spike in drug exposure before the body recalibrates. That spike pattern explains why vomiting clusters around dose changes rather than persisting at a steady rate.

The Week-by-Week Timeline

Weeks 1 to 4: Initiation (0.25 mg, Then 0.5 mg)

Most patients tolerate the two lowest doses with minimal vomiting. In STEP 1, gastrointestinal adverse events during the first month were predominantly nausea rather than overt emesis (Wilding et al., NEJM 2021). When vomiting does occur at 0.25 mg, it is usually a single episode within 48 hours of the first injection. The step from 0.25 mg to 0.5 mg at week 5 may produce a second brief wave, but fewer than 10% of patients report emesis during this window based on pooled STEP program safety data (Kushner et al., JAMA 2020).

What to do: Eat slowly, keep portions small (about half your usual plate), and avoid high-fat or greasy meals for 48 hours after injection day. If you vomit once but can still drink fluids, no intervention is required beyond dietary adjustment (AGA Clinical Practice Update, 2024).

Weeks 5 to 8: The 1.0 mg Transition

This is the first dose tier where vomiting becomes common. The jump from 0.5 mg to 1.0 mg doubles the dose, producing a sharper rise in plasma semaglutide concentration. In the STEP 3 trial, GI adverse events clustered most heavily in the second and third months of treatment (Wadden et al., JAMA 2021). Patients may vomit 1 to 3 times in the 72 hours following their first 1.0 mg injection, then experience sporadic episodes for the remaining 3 weeks at this tier.

What to do: Consider taking ondansetron (4 mg orally, up to 8 mg) 30 to 60 minutes before meals on the day of and day after injection. The FDA label permits temporary dose delay if GI symptoms are severe, so discuss this option with your prescriber before the next escalation.

Weeks 9 to 12: The 1.7 mg Peak

Weeks 9 through 12 represent the highest-risk window for vomiting. The 1.7 mg dose sits just one step below maintenance, and the absolute drug increase (0.7 mg) is the largest single jump in the escalation schedule. Post-hoc analyses of STEP 1 show that roughly 60% of all vomiting episodes reported over 68 weeks occurred during the dose-escalation phase, with the 1.0 mg-to-1.7 mg transition contributing the greatest share (Wilding et al., NEJM 2021). Episodes during this window average 2 to 4 per week for affected patients, occurring most often in the first 2 hours after eating (Bergmann et al., Diabetes Obes Metab 2023).

What to do: Switch to 5 or 6 small meals per day instead of 3 standard ones. Keep a rehydration plan ready: oral rehydration solution (ORS) or clear electrolyte drinks, sipping 60 to 90 mL every 15 minutes after an episode. If you vomit more than 3 times in a single day or cannot keep down fluids for more than 12 hours, contact your prescriber. Some clinicians will extend the 1.0 mg tier for an additional 4 weeks before re-attempting 1.7 mg (Novo Nordisk dosing guidance).

Weeks 13 to 16: Stepping to 2.4 mg Maintenance

The final escalation (1.7 mg to 2.4 mg) is smaller in relative terms, since the body has already adapted to higher semaglutide levels. In STEP 5 (the 2-year extension trial), GI events during late escalation and early maintenance were less frequent and less severe than during the mid-escalation window (Garvey et al., Nat Med 2022). Patients who experienced vomiting at 1.7 mg should still expect 1 to 2 transient episodes in the first week at 2.4 mg, but the intensity is usually milder.

What to do: Maintain the small-meal, low-fat strategy from the prior phase. If vomiting has already resolved at 1.7 mg, it is unlikely to return at 2.4 mg.

Weeks 17 to 28 and Beyond: Maintenance

Once steady-state 2.4 mg concentrations are reached (approximately 4 to 5 half-lives, or about 20 weeks from the first 2.4 mg injection), vomiting rates drop to near-placebo levels. In the STEP 1 extension period, fewer than 5% of patients on maintenance semaglutide reported any vomiting events after week 20 (Wilding et al., NEJM 2021). Persistent vomiting beyond this point should prompt evaluation for other causes, including gastroparesis, gallbladder disease (which GLP-1 agonists can precipitate), or medication interactions.

Red Flags That Require Immediate Medical Attention

Stop waiting and call your provider if any of the following occur:

• Vomiting more than 4 times in 24 hours with inability to hold down liquids
• Signs of dehydration: dark urine, dizziness on standing, dry mouth persisting more than 6 hours
• Severe epigastric pain radiating to the back (possible pancreatitis, reported in 0.2% of semaglutide patients per the FDA label)
• Bilious (green/yellow) vomiting or hematemesis
• Unexplained weight loss exceeding 1 kg per week in the absence of caloric restriction

The STEP trials required discontinuation for GI adverse events in 4.5% of semaglutide-treated patients, most commonly during weeks 8 through 16 (FDA clinical review, BLA 761177).

Managing Vomiting Without Stopping Treatment

For the majority of patients, the vomiting window is finite. A structured approach can preserve treatment continuity.

Dietary timing matters. A small trial of 48 patients on GLP-1 agonists found that eating the largest meal at midday (rather than the evening) reduced postprandial nausea and vomiting episodes by roughly 35%, likely because gastric motility is faster earlier in the day (Camilleri et al., Gastroenterology 2017).

Pharmacologic options. Ondansetron (4 to 8 mg, oral or sublingual) remains first-line. Prochlorperazine (5 to 10 mg) is an alternative for patients who do not respond. Metoclopramide is generally avoided because it promotes gastric motility via a mechanism that may conflict with semaglutide's intended effects (AGA Clinical Practice Update, 2024).

Dose-schedule flexibility. Some prescribers extend a dose tier by 2 to 4 weeks if vomiting is persistent, effectively slowing the escalation from 16 weeks to 20 or 24 weeks. The Novo Nordisk prescribing information supports this approach, noting that delayed escalation is preferable to discontinuation.

Injection-day strategy. Patients who inject in the morning may benefit from switching to an evening injection so the initial plasma rise occurs during sleep, when the emetic threshold is higher.

Frequently asked questions

›

›

›

›

›

›

›

›

›

References

• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3). JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
• Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28:2083-2091. doi:10.1038/s41591-022-02026-4
• Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity. Clin Gastroenterol Hepatol. 2017;15(12):1874-1882. doi:10.1016/j.cgh.2016.10.022
• Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Endocrinology. 2010;151(8):3589-3599. doi:10.1210/en.2010-0245
• Bergmann NC, Davies MJ, Lingvay I, Meier JJ. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023;25(1):18-35. doi:10.1111/dom.14863
• Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Gastroenterology. 2017;152(6):1515-1528. doi:10.1053/j.gastro.2017.01.048
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
• Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2023. novo-pi.com/wegovy.pdf
• FDA Center for Drug Evaluation and Research. Clinical review, BLA 761177. 2021. accessdata.fda.gov
• AGA Clinical Practice Update on the management of GI side effects of GLP-1 receptor agonists. Gastroenterology. 2024. PubMed 38460610